Kaleido BioSciences: Harnessing proprietary small molecule chemistry platform to develop microbiome metabolic therapies (MMT) in indications spanning I-O, nitrogen metabolism, metabolic diseases, and CNS. Data expected in 4Q20 from Ph 2 trial (UNLOCKED) of KB195 in patients with urea cycle disorder (UCD) inadequately controlled on SOC, study of KB109 (VITORA) in patients colonized with multi-drug resistant pathogens, and in vivo findings from ongoing programs in I-O, cardiometabolic and liver diseases.
Based in...
US - New England
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
65 Hayden Ave
Lexington, MA 02421
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Kaleido Biosciences, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Flagship Ventures Management, Inc. 64.90 19,360,710 114.23 13F 6/30/20
Fidelity Management & Research Co. LLC 9.10 2,714,722 16.02 13F 6/30/20
HarbourVest Partners LLC 6.15 1,833,832 10.82 13F 6/30/20
Palo Alto Investors LP 2.64 786,400 4.64 13F 6/30/20
The Vanguard Group, Inc. 1.82 544,776 3.21 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 1.76 524,697 3.10 13F 6/30/20
Artal Group SA 1.68 500,500 2.95 13F 6/30/20
Federated Global Investment Management Corp. 1.68 500,000 2.95 13F 6/30/20
Baillie Gifford & Co. 1.47 440,000 2.60 13F 6/30/20
BlackRock Fund Advisors 1.19 355,278 2.10 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.